Group 1: Guizhou Moutai - Guizhou Moutai achieved a net profit of 45.403 billion yuan in the first half of 2025, an increase of 8.89% year-on-year [1] - The company's operating income for the same period was 89.389 billion yuan, reflecting a growth of 9.1% year-on-year [1] - Basic earnings per share were reported at 36.18 yuan per share [1] Group 2: Weixing New Materials - Weixing New Materials reported a net profit of 271 million yuan in the first half of 2025, a decrease of 20.25% year-on-year [1] - The company's operating income was 2.078 billion yuan, down 11.33% year-on-year [1] - The company plans to distribute a cash dividend of 1 yuan per 10 shares [1] Group 3: Jianyuan Trust - Jianyuan Trust's net profit for the first half of 2025 was 40.2897 million yuan, an increase of 13.36% year-on-year [1] - The company achieved an operating income of 15 million yuan, a significant growth of 84.89% year-on-year [1] - Basic earnings per share were reported at 0.0041 yuan per share [1][2] Group 4: Weili - Weili won a bid for a leachate treatment project, expected to generate an annual revenue of approximately 61 million yuan [1] - The project has a total expected revenue of about 610 million yuan over a 10-year operational period [1] - The project includes a 0.5-year construction period followed by a 10-year operational period [1] Group 5: Tianjun Wind Power - Tianjun Wind Power provided a guarantee for a credit line of 150 million yuan for its wholly-owned subsidiary [1] - The guarantee covers the principal amount, interest, penalties, and other related costs [1] - The guarantee period is three years from the maturity of the main contract [1] Group 6: Jiangshan Oupai - Jiangshan Oupai's wholly-owned subsidiary completed the registration for a change in business type [1] - The subsidiary is now classified as a limited liability company [1] Group 7: Ningbo Port - Ningbo Port announced the resignation of independent director Yan Guoqing due to personal reasons [1] Group 8: Yangfan New Materials - Yangfan New Materials reported a net profit of 23.1372 million yuan in the first half of 2025, marking a turnaround from losses [1] - The company's total operating revenue was 473 million yuan, an increase of 47.93% year-on-year [1] Group 9: Zhongguancun - Zhongguancun's subsidiary received a drug registration certificate for a new injection [1] - The company also announced that another product passed the consistency evaluation for generic drugs [1] Group 10: Hengtong Oriental - Hengtong Oriental is under investigation by the China Securities Regulatory Commission for suspected information disclosure violations [1] Group 11: Quzhou Development - Quzhou Development plans to acquire 95.46% of Xian Dao Electronics and will resume trading on August 13, 2025 [1] Group 12: Jiangsu Sop - Jiangsu Sop reported a net profit of 102 million yuan in the first half of 2025, a decrease of 13.01% year-on-year [1] - The company's operating income was 3.158 billion yuan, down 1.08% year-on-year [1] Group 13: Fudan Fuhua - Fudan Fuhua's subsidiary plans to invest 48.87 million yuan in a capital increase for another company [1] Group 14: Shaanxi Huada - Shaanxi Huada is planning to acquire 100% of Huajing Microelectronics and has suspended trading [1]

Core Viewpoint - Tianyu Co., Ltd. has received CEP certification for its raw material drug, Telmisartan, which is used for treating primary hypertension and reducing cardiovascular risk, allowing it to sell in European markets and other regions that recognize the certification [1] Company Overview - As of August 12, 2025, Tianyu Co., Ltd. stock price is 29.28 yuan, down 1.65% from the previous trading day [1] - The company reported a trading volume of 464 million yuan and a turnover rate of 7.50% on the same day [1] - Tianyu Co., Ltd. specializes in the research, production, and sales of pharmaceutical intermediates, active pharmaceutical ingredients, and formulations, covering treatment areas such as hypertension, hyperlipidemia, and diabetes [1] Financial Flow - On August 12, the net outflow of main funds was 24.54 million yuan, while the net inflow over the past five days was 11.32 million yuan [1]

Group 1 - The core point of the article is that Tianyu Co., Ltd. has received the CEP certificate from the European Medicines Agency for the active pharmaceutical ingredient of Telmisartan, which is used for treating primary hypertension and reducing cardiovascular risk [1] Group 2 - The announcement highlights the significance of the CEP certificate in ensuring the quality and compliance of the pharmaceutical product in the European market [1] - Telmisartan is specifically indicated for the treatment of primary hypertension and plays a role in lowering cardiovascular risk, indicating its importance in the healthcare sector [1]

Group 1 - The company Tianyu Co., Ltd. (300702.SZ) has received the Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines (EDQM) for the active pharmaceutical ingredient (API) of Telmisartan [1] - Telmisartan is used for the treatment of primary hypertension and for reducing cardiovascular risk [1]